Core Viewpoint - Sonnet BioTherapeutics Holdings, Inc. has appointed Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025, to enhance its business development and partnering strategy as the company progresses its clinical initiatives [1][3]. Company Overview - Sonnet is a clinical-stage biotechnology company focused on developing targeted immunotherapeutic drugs, utilizing its proprietary FHAB (Fully Human Albumin-Binding) technology to optimize the safety and efficacy of biologic drugs [6]. - The FHAB platform allows for the development of modular, plug-and-play constructs for various therapeutic classes, including cytokines, peptides, antibodies, and vaccines [6]. Leadership Appointment - Dr. McAndrew brings over 30 years of experience in business development and transactional agreements in the biopharmaceutical sector, having previously served as Vice President and Senior Vice President of Business Development at Sonnet [2][4]. - His role will focus on establishing key partnerships and driving the company's strategy forward, particularly in relation to the clinical development of its FHAB assets [4]. Clinical Programs - Sonnet's lead program, SON-1010 (IL-12-FHAB), is in development for solid tumors and ovarian cancer, currently undergoing a Phase 1/2a study in collaboration with Roche [7]. - The company is also advancing SON-1210 (IL12-FHAB-IL15) for pancreatic cancer and SON-080 for Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy, with promising results from earlier trials [7][8]. Previous Experience of Dr. McAndrew - Prior to joining Sonnet, Dr. McAndrew held senior roles at Oncobiologics, Inc. and Bristol-Myers Squibb Company, where he was responsible for business development, licensing, and revenue growth strategies [2][4]. Educational Background - Dr. McAndrew holds a Ph.D. in Cellular and Molecular Biology, a Master's in Molecular Genetics, and a Bachelor's in Science, showcasing a strong academic foundation relevant to his role [5].
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer